Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Versluis, J; In't Hout, F E; Devillier, R; van Putten, W L; Manz, M G; Vekemans, M C; Legdeur, M C; Passweg, J R; Maertens, J; Kuball, J; Biemond, B J; Valk, P J; van der Reijden, B A; Meloni, G; Schouten, H C; Vellenga, E; Pabst, T; Willemze, R; Löwenberg, B; Ossenkoppele, G; Baron, F; Huls, G; Cornelissen, J J (2016). Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia, 31(1):26-33.

Cornelissen, J J; Versluis, J; Passweg, J R; van Putten, W L; Manz, M G; Maertens, J; Beverloo, H B; Valk, P J; van Marwijk, Kooy M; Wijermans, P W; Schaafsma, M R; Biemond, B J; Vekemans, M C; Breems, D A; Verdonck, L F; Fey, M F; Jongen-Lavrencic, M; Janssen, J J; Huls, G; Kuball, J; Pabst, T; Graux, C; Schouten, H C; Gratwohl, A; Vellenga, E; Ossenkoppele, G; Löwenberg, B (2015). Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia, 29(5):1041-1050.

Terwijn, M; van Putten, W L; Kelder, A; van der Velden, V H; Brooimans, R A; Pabst, T; Maertens, J; Boeckx, N; de Greef, G E; Valk, P J; Preijers, F W; Huijgens, P C; Dräger, A M; Schanz, U; Jongen-Lavrecic, M; Biemond, B J; Passweg, J R; van Gelder, M; Wijermans, P; Graux, C; Bargetzi, M; Legdeur, M C; Kuball, J; de Weerdt, O; Chalandon, Y; Hess, U; Verdonck, L F; Gratama, J W; Oussoren, Y J; Scholten, W J; Slomp, J; Snel, A N; Vekemans, M C; Löwenberg, B; Ossenkoppele, G J; Schuurhuis, G J (2013). High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A Study. Journal of Clinical Oncology, 31(31):3889-3897.

Löwenberg, B; Pabst, T; Vellenga, E; van Putten, W; Schouten, H C; Graux, C; Ferrant, A; Sonneveld, P; Biemond, B J; Gratwohl, A; de Greef, G E; Verdonck, L F; Schaafsma, M R; Gregor, M; Theobald, M; Schanz, U; Maertens, J; Ossenkoppele, G J (2011). Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364(11):1027-1036.

This list was generated on Mon Oct 23 01:43:55 2017 CEST.